Your browser doesn't support javascript.
loading
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
Yu, Evan Y; Kolinsky, Michael P; Berry, William R; Retz, Margitta; Mourey, Loic; Piulats, Josep M; Appleman, Leonard J; Romano, Emanuela; Gravis, Gwenaelle; Gurney, Howard; Bögemann, Martin; Emmenegger, Urban; Joshua, Anthony M; Linch, Mark; Sridhar, Srikala; Conter, Henry J; Laguerre, Brigitte; Massard, Christophe; Li, Xin Tong; Schloss, Charles; Poehlein, Christian H; de Bono, Johann S.
Afiliação
  • Yu EY; Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Research Center, G4-830, Seattle, WA, USA. Electronic address: evanyu@u.washington.edu.
  • Kolinsky MP; Department of Oncology, Cross Cancer Institute, Edmonton, AB, Canada.
  • Berry WR; Department of Medical Oncology, Duke Cancer Center Cary, Cary, NC, USA.
  • Retz M; Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany.
  • Mourey L; Department of Medical Oncology, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France.
  • Piulats JM; Department of Medical Oncology, Catalan Institute of Oncology, Barcelona, Spain.
  • Appleman LJ; Department of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Romano E; Department of Medical Oncology, Center for Cancer Immunotherapy, Institut Curie, Paris, France.
  • Gravis G; Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille Université, Marseille, France.
  • Gurney H; Department of Medical Oncology, Macquarie University, Sydney, NSW, Australia.
  • Bögemann M; Department of Urology, University Hospital Münster, Münster, Germany.
  • Emmenegger U; Division of Medical Oncology, Odette Cancer Centre and Sunnybrook Research Institute, Toronto, ON, Canada.
  • Joshua AM; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia.
  • Linch M; Department of Oncology, University College London Hospital and UCL Cancer Institute, London, UK.
  • Sridhar S; Cancer Clinical Research Unit, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Conter HJ; Department of Medical Oncology, University of Western Ontario, Brampton, ON, Canada.
  • Laguerre B; Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.
  • Massard C; Department of Drug Development, Gustave Roussy Cancer Campus and Université Paris-Sud, Villejuif, France; Department of Medical Oncology, Gustave Roussy Cancer Campus and Université Paris-Sud, Villejuif, France.
  • Li XT; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Schloss C; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Poehlein CH; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.
  • de Bono JS; Division of Clinical Studies, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK.
Eur Urol ; 82(1): 22-30, 2022 07.
Article em En | MEDLINE | ID: mdl-35397952
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Eur Urol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Eur Urol Ano de publicação: 2022 Tipo de documento: Article